On Tuesday, Biophytis unveiled the design of its Phase 2 clinical trial in obesity, a potential market that the biotech company considers important.

The trial will enroll 164 overweight or obese patients already treated with GLP-1 weight-loss drugs, to whom 350 mg of its BIO101 (20-hydroxyecdysone) will be administered for 21 weeks.

The company believes that its BIO101 could help preserve muscle function in obese patients treated for weight loss with GLP-1.

The primary efficacy endpoint is to be muscle strength measured by knee extension, with a six-minute walking test and other performance tests as secondary endpoints.

Biophytis says it hopes the drug candidate will enter phase 2 clinical trials in mid-2024, with first results potentially available as early as 2025.

The biotech is preparing to file an application to start the study in the USA in the coming weeks.

Copyright (c) 2024 CercleFinance.com. All rights reserved.